SU858830A1 - Agent for treating cardiac rythm distortions - Google Patents
Agent for treating cardiac rythm distortions Download PDFInfo
- Publication number
- SU858830A1 SU858830A1 SU742069505A SU2069505A SU858830A1 SU 858830 A1 SU858830 A1 SU 858830A1 SU 742069505 A SU742069505 A SU 742069505A SU 2069505 A SU2069505 A SU 2069505A SU 858830 A1 SU858830 A1 SU 858830A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- potassium
- distortions
- agent
- treating cardiac
- medicine
- Prior art date
Links
Description
Изобретение относитс к препаратам медицинского назначени , в част ности дл лечени сердечно-сосудист системы. Известны препараты дл лечени нарушений ритма сердца, содержащие ионы кали в сочетании с а|шонами хлора, аспарагината fO Однако при введении в организм хлорида кали из организма вымывают с анионы угольной кислоты, вл ющиес одним из основных компонентов щелочного резерва организма. Известно применение кали гидрокарбоната в качестве аналитического реактива С2. Цель изобретени - расшир.е1шё ассортимента средств дл лече1ш на рушени ритма сердца. Поставленна цель достигаетс тем, что в качестве средств дл лечени нарушений ритма сердца примен ют калий гидрокАрбонат. Дл лечени нарушений ритма сердца калий гидрокарбонат ввод т внутривенно капельно в виде 0,5-1%-ного раствора на изотоническом растворе хлорида натри ежедневно в суточной дозе 2-4. Ректально калий гидрокарбонат ввод т в свечах ежедневно 1-2 раза в день при содержании в одной свече 0,7-0,5-0,3 г кали гидрокарбоната. Комбинированный способ лечени предусматривает внутривенное введение 2-4 г кали гидрокарбоната через день и ежедневное ректальное введение свечей. При введении в организм ионов кали в сочетании с анионами угольной кислоты в клетках понижаетс концентраци водорода, снижаетс ацидос, повьшаетс валентность буферных анионов и тем самым создаиотс услови дл вхождени ионов кали в клетки. Препарат предназначен дл восста38588304The invention relates to preparations for medical purposes, in particular for the treatment of the cardiovascular system. Preparations for the treatment of cardiac arrhythmias are known that contain potassium ions in combination with chlorine chlorides, asparaginate fO. However, when potassium chloride is introduced into the body, the anions of carbonic acid, which are one of the main components of the body's alkaline reserve, are washed out of the body. The use of potassium bicarbonate as an analytical reagent C2 is known. The purpose of the invention is to expand the range of products for medical treatment in the rhythm of the heart. This goal is achieved by using potassium hydrocarbonate as agents for treating heart rhythm disorders. For the treatment of cardiac arrhythmias, potassium bicarbonate is administered intravenously in the form of a 0.5-1% solution of sodium chloride with an isotonic solution of sodium chloride daily in a daily dose of 2-4. Rectally, potassium bicarbonate is injected in candles daily, 1-2 times a day, when the content in one candle is 0.7-0.5-0.3 g of potassium bicarbonate. The combined treatment method involves intravenous administration of 2-4 g of potassium bicarbonate every other day and daily rectal administration of suppositories. When potassium ions are introduced into the organism in combination with carbonic anions in the cells, the concentration of hydrogen decreases, the acidos decrease, the valence of the buffer anions increases, and thus conditions for the entry of potassium ions into the cells. The drug is intended to restore 38588304
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU742069505A SU858830A1 (en) | 1974-10-23 | 1974-10-23 | Agent for treating cardiac rythm distortions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU742069505A SU858830A1 (en) | 1974-10-23 | 1974-10-23 | Agent for treating cardiac rythm distortions |
Publications (1)
Publication Number | Publication Date |
---|---|
SU858830A1 true SU858830A1 (en) | 1981-08-30 |
Family
ID=20599021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU742069505A SU858830A1 (en) | 1974-10-23 | 1974-10-23 | Agent for treating cardiac rythm distortions |
Country Status (1)
Country | Link |
---|---|
SU (1) | SU858830A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990004403A1 (en) * | 1988-10-21 | 1990-05-03 | The Regents Of The University Of California | Treatment of hypertension |
-
1974
- 1974-10-23 SU SU742069505A patent/SU858830A1/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990004403A1 (en) * | 1988-10-21 | 1990-05-03 | The Regents Of The University Of California | Treatment of hypertension |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kelly et al. | Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities | |
Iseri et al. | Magnesium and potassium therapy in multifocal atrial tachycardia | |
Tzivoni et al. | Treatment of torsade de pointes with magnesium sulfate. | |
Dowdy et al. | Ventricular arrhythmias induced by succinylcholine in digitalized patients: a preliminary report | |
Meilman et al. | Clinical studies on veratrum alkaloids: I. The action of protoveratrine and veratridine in hypertension | |
Da Silva et al. | Verapamil acute self-poisoning | |
Page et al. | Interrelationships between cardiac effects of ouabain, hypocalcemia and hyperkalemia | |
Citrin et al. | Massive digoxin overdose: Observations on hyperkalaemia and plasma digoxin levels | |
SU858830A1 (en) | Agent for treating cardiac rythm distortions | |
Jick et al. | The effect of calcium chelation on cardiac arrhythmias and conduction disturbances | |
Cleghorn et al. | The treatment of Addison's disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate) | |
Nathan et al. | Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent | |
Berg et al. | Friedreich's ataxia with acute cardiomyopathy | |
Shiraki et al. | Complete atrioventricular block secondary to lithium therapy | |
US2259492A (en) | Therapeutic preparation of bismuth and method of preparing same | |
Khalsa et al. | Effect of Oral Verapamil on Ventricular Irregularity in Long‐Standing Atrial Fibrillation. | |
Horler et al. | Hypertensive crisis due to pargyline and metaraminol | |
Burrage et al. | Maintenance cortisone in severe bronchial asthma | |
WOLINTZ et al. | Stokes-Adams syndrome and atrial arrhythmias as the presenting symptoms of myotonic dystrophy, with response to electrocardioversion | |
IL36587A (en) | Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions | |
SU1435255A1 (en) | Method of recovering antithromogenic activity of vessel wall of cardiological patients | |
Gilbert et al. | Failure of corticotropin to prevent acute hemolytic anemia due to sulfapyridine | |
Gasperetti | Conduction abnormalities complicating carbamazepine therapy | |
SU789109A1 (en) | Method of treating children's active rheumatism | |
Heilig et al. | The influence of intravenous injections of quinine on the myocardium |